2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1770

Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis
Abstract Number: 1771

Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center
Abstract Number: 1772

Apremilast in Refractory Oral and/or Genital Ulcers in Behçet’s Disease. Multicenter Study of 37 Cases
Abstract Number: 1773

Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behçet’s Disease. National Multicenter Study of 177 Cases
Abstract Number: 1774

The Relationship between Serum Cholinesterase, Dickkopf-1 and Number of Organ Involvement in Japanese Patients with IgG4-Related Disease
Abstract Number: 1775

IgG4-Related Disease, Clinical Series on Chilean Patients
Abstract Number: 1776

Clinical Significance of Allergy in IgG4-Related Disease
Abstract Number: 1777

Factors Related to Deterioration of IgG4-Related Disease in Untreated Patients with IgG4-Related Disease
Abstract Number: 1778

Comparison of Clinical and Angiographic Features of Arterial Involvement in Takayasu’s Arteritis and Behcet’s Disease
Abstract Number: 1779

Is the Number of IgG4+ Plasma Cells Observed By Immunostaining Important Beyond Its Diagnostic Utility in IgG4-Related Disease?
Abstract Number: 1780

Shear Wave Elastography in the Evaluation of Submandibular Gland Characteristics in IgG4-Related Disease
Abstract Number: 1781

Retrospective Analysis of IgG4-RD Patient Population at the Cleveland Clinic between 2007-2017
Abstract Number: 1782

Cigarette Smoking Is a Risk Factor for IgG4-Related Disease
Abstract Number: 1783

Salivary Gland Disease in IgG4-Related Disease Is Associated with Allergic Histories
Abstract Number: 1784

Serum IgG4 Test Characteristics: Immunonephelometry Versus Liquid Chromatography Tandem Mass Spectrometry

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].